Transcription Factor PAX6 As a Novel Prognostic Factor and Putative Tumour Suppressor in Non-small Cell Lung Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2018 Mar 24

PMID 29568088

Citations 9

Authors

Yury Kiselev

Sigve Andersen

Charles Johannessen

Bjorn Fjukstad

Karina Standahl Olsen

Helge Stenvold

Samer Al-Saad

Tom Donnem

Elin Richardsen

Roy M Bremnes

Lill-Tove Rasmussen Busund

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer deaths. Novel predictive biomarkers are needed to improve treatment selection and more accurate prognostication. PAX6 is a transcription factor with a proposed tumour suppressor function. Immunohistochemical staining was performed on tissue microarrays from 335 non-small cell lung cancer (NSCLC) patients for PAX6. Multivariate analyses of clinico-pathological variables and disease-specific survival (DSS) was carried out, and phenotypic changes of two NSCLC cell lines with knockdown of PAX6 were characterized. While PAX6 expression was only associated with a trend of better disease-specific survival (DSS) (p = 0.10), the pN+ subgroup (N = 103) showed significant correlation between high PAX6 expression and longer DSS (p = 0.022). Median survival for pN + patients with high PAX6 expression was 127.4 months, versus 22.9 months for patients with low PAX6 expression. In NCI-H661 cells, knockdown of PAX6 strongly activated serum-stimulated migration. In NCI-H460 cells, PAX6 knockdown activated anchorage-independent growth. We did not observe any significant effect of PAX6 on proliferation in either of cell lines. Our findings strongly support the proposition of PAX6 as a valid and positive prognostic marker in NSCLC in node-positive patients. There is a need for further studies, which should provide mechanistical explanation for the role of PAX6 in NSCLC.

Citing Articles

Profilin 2 isoform expression is associated with lung metastasis of colorectal cancer according to a comprehensive gene expression study using a mouse model.

Toyota N, Tsuruta M, Tajima Y, Shigeta K, Okabayashi K, Hasegawa H Oncol Lett. 2024; 28(2):381.

PMID: 38939626 PMC: 11209866. DOI: 10.3892/ol.2024.14514.

Synthetic Lethality between Cohesin and WNT Signaling Pathways in Diverse Cancer Contexts.

Pallotta M, Di Nardo M, Musio A Cells. 2024; 13(7.

PMID: 38607047 PMC: 11011321. DOI: 10.3390/cells13070608.

MicroRNA-383: A tumor suppressor miRNA in human cancer.

Jafarzadeh A, Noori M, Sarrafzadeh S, Tamehri Zadeh S, Nemati M, Chatrabnous N Front Cell Dev Biol. 2022; 10:955486.

PMID: 36313570 PMC: 9608775. DOI: 10.3389/fcell.2022.955486.

KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.

Rudd M, Hansen N, Zhang X, Urick M, Zhang S, Merino M PLoS One. 2022; 17(1):e0251286.

PMID: 35081118 PMC: 8791453. DOI: 10.1371/journal.pone.0251286.

LncRNA DUXAP10 Upregulation and the Hedgehog Pathway Activation Are Critically Involved in Chronic Cadmium Exposure-Induced Cancer Stem Cell-Like Property.

Lin H, Wang Z, Yang C Toxicol Sci. 2021; 184(1):33-45.

PMID: 34373904 PMC: 8677432. DOI: 10.1093/toxsci/kfab099.

References

Huang B, Luo Q, Han Y, Li X, Cao L, Wu L . microRNA-223 promotes the growth and invasion of glioblastoma cells by targeting tumor suppressor PAX6. Oncol Rep. 2013; 30(5):2263-9. DOI: 10.3892/or.2013.2683. View

Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund L, Bremnes R . Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol. 2008; 3(9):963-70. DOI: 10.1097/JTO.0b013e3181834f52. View

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M . Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. DOI: 10.1038/nbt1210-1248. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Al-Shibli K, Donnem T, Al-Saad S, Persson M, Bremnes R, Busund L . Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008; 14(16):5220-7. DOI: 10.1158/1078-0432.CCR-08-0133. View

Chien W, Yin D, Gui D, Mori A, Frank J, Said J . Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res. 2006; 4(8):591-8. DOI: 10.1158/1541-7786.MCR-06-0029. View

Morgensztern D, Ng S, Gao F, Govindan R . Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2009; 5(1):29-33. DOI: 10.1097/JTO.0b013e3181c5920c. View

Wolf L, Yang Y, Wang J, Xie Q, Braunger B, Tamm E . Identification of pax6-dependent gene regulatory networks in the mouse lens. PLoS One. 2009; 4(1):e4159. PMC: 2612750. DOI: 10.1371/journal.pone.0004159. View

10.

Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund L, Bremnes R . Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010; 116(18):4318-25. DOI: 10.1002/cncr.25333. View

11.

Andersen S, Donnem T, Al-Shibli K, Al-Saad S, Stenvold H, Busund L . Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. PLoS One. 2011; 6(5):e19773. PMC: 3095634. DOI: 10.1371/journal.pone.0019773. View

12.

Wu G, Ji H . ChIPXpress: using publicly available gene expression data to improve ChIP-seq and ChIP-chip target gene ranking. BMC Bioinformatics. 2013; 14:188. PMC: 3684512. DOI: 10.1186/1471-2105-14-188. View

13.

Walter R, Mairinger F, Werner R, Ting S, Vollbrecht C, Theegarten D . SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString). Future Oncol. 2015; 11(7):1027-36. DOI: 10.2217/fon.15.18. View

14.

Kiselev Y, Eriksen T, Forsdahl S, Nguyen L, Mikkola I . 3T3 cell lines stably expressing Pax6 or Pax6(5a)--a new tool used for identification of common and isoform specific target genes. PLoS One. 2012; 7(2):e31915. PMC: 3285655. DOI: 10.1371/journal.pone.0031915. View

15.

Shaham O, Menuchin Y, Farhy C, Ashery-Padan R . Pax6: a multi-level regulator of ocular development. Prog Retin Eye Res. 2012; 31(5):351-76. DOI: 10.1016/j.preteyeres.2012.04.002. View

16.

Simpson T, Price D . Pax6; a pleiotropic player in development. Bioessays. 2002; 24(11):1041-51. DOI: 10.1002/bies.10174. View

17.

Zhao X, Yue W, Zhang L, Ma L, Jia W, Qian Z . Downregulation of PAX6 by shRNA inhibits proliferation and cell cycle progression of human non-small cell lung cancer cell lines. PLoS One. 2014; 9(1):e85738. PMC: 3893268. DOI: 10.1371/journal.pone.0085738. View

18.

Stewart D . Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010; 75(3):173-234. PMC: 2888634. DOI: 10.1016/j.critrevonc.2009.11.006. View

19.

Bai S, Li B, Zhang H, Jonas J, Zhao B, Shen L . Pax6 regulates proliferation and apoptosis of human retinoblastoma cells. Invest Ophthalmol Vis Sci. 2010; 52(7):4560-70. DOI: 10.1167/iovs.10-5487. View

20.

Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund L, Bremnes R . Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size. Clin Lung Cancer. 2011; 12(2):106-15. DOI: 10.1016/j.cllc.2011.03.005. View